


















![]()
UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer May 17, 2026 8:30 AM EDT
Company Participants
Elizabeth Barrett - President, CEO & Director
Mark Schoenberg - Chief Medical Officer
Vincent Perrone - Senior Director of Investor Relations
Conference Call Participants
Aaron Berger
Karim Chamie
Jennifer Linehan
Nicholas Lorusso - TD Cowen, Research Division
Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division
Mohamad Amin Makarem - Jefferies LLC, Research Division
Kelsey Goodwin - Piper Sandler & Co., Research Division
Kyuwon Choi - Goldman Sachs Group, Inc., Research Division
Kevin DeGeeter - Ladenburg Thalmann & Co. Inc., Research Division
Presentation
Elizabeth Barrett
President, CEO & Director
Good morning, everyone. Hi. I'm Liz Barrett, and I'm the CEO of UroGen Pharma. Thank you for joining us today. We're here in Washington, D.C. at the AUA. Very excited to be here, a very exciting time for our company. I'm going to talk to you a little bit through the agenda today, and then we have an exciting agenda for you, and then there'll be an opportunity for Q&A at the end.
So of course, our normal disclaimers here. I won't read them. Thank goodness. We won't have time for that. We wouldn't have time for anything else. The agenda, I'm exciting after I'm going to make a few opening remarks, show you a few slides. I'm going to turn it over to Dr. Schoenberg and he's going to moderate a panel discussion with our esteemed urologists. You'll be excited to hear from them. All of them have had experience with ZUSDURI, and we're very excited about that. But more importantly, actually, I have the opportunity to interview and share with you a story of a patient who has received ZUSDURI and recently received a complete response. So I'm very excited about that, and I think you'll enjoy it. And then again, as I said, we'll have an opportunity for Q&A.
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。